OSE Immunotherapeutics SA is set to resume recruitment into a Phase 3 trial of patients with non-small cell lung cancer (NSCLC) following a pause in June to enable investigators to have more time to assess the effect of the treatment which is a neoantigen therapy called Tedopi.
